Please login to the form below

Not currently logged in
Email:
Password:

Teva sues Apotex to block generic Coreg

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Apotex, Teva and other generic-drug makers won FDA approval to sell the generic version on 5 September 2007. Teva says that it owns four patents which cover various forms and processes to make carvedilol.

To sell carvedilol, says Teva, Apotex might have to purchase the compound made using the patented process. Apotex has not supplied the necessary data required to rule whether the generic uses patented processes or not. Teva has filed for a court order to prevent patent infringement by Apotex.

For H1 FY07, Coreg posted sales of USD 854m and analysts say that the annual generic market for carvedilol could be worth as much as USD 50m.

30th September 2008

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...
Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...